Results 191 to 200 of about 28,869 (265)

Deep sequencing analysis of hepatitis B virus in patients with incomplete response to tenofovir alafenamide fumarate treatment. [PDF]

World J Hepatol
Yamada N, Igarashi H, Murayama A, Suzuki M, Yasuda K, Saito M, Isogawa M, Kato T.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Emtricitabine + tenofovir alafenamide for the treatment of HIV

Expert Opinion on Pharmacotherapy, 2017
Tenofovir alafenamide is a new oral prodrug of tenofovir resulting in relatively low plasma levels and rapid uptake into peripheral blood mononuclear cells in its active form. The United States Food and Drug Administration has now approved this drug coformulated with elvitegravir/cobicistat/emtricitabine, rilpivirine/emtricitabine and emtricitabine ...
Eric S Daar
exaly   +3 more sources

Tenofovir-alafenamide

Reactions Weekly
semanticscholar   +4 more sources

Tenofovir Alafenamide.

The Annals of pharmacotherapy, 2017
To review the pharmacology, efficacy, safety, and place in therapy for tenofovir alafenamide (TAF).A search using PubMed was conducted (2004 to May 2016) using the following keywords: tenofovir alafenamide, TAF, and GS-7340. Articles were evaluated for content, and bibliographies were reviewed.
Amanda K, Gibson, Bhavik M, Shah, Puja H, Nambiar, Jason J, Schafer   +3 more
openaire   +2 more sources

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials [PDF]

Lancet, The, 2015
none27siBackground Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir
Paul E Sax, Michael T Yin, Fa Post
exaly   +3 more sources

Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.

The Lancet Gastroenterology and Hepatology
BACKGROUND Current guidelines for chronic hepatitis B recommend antiviral therapy for individuals with non-cirrhotic chronic hepatitis B only if they have significant liver fibrosis or elevated alanine aminotransferase (ALT) concentrations.
Y. Lim, Ming‐Lung Yu, Jonggi Choi, Chi-Yi Chen, Won Choi, Wonseok Kang, Gi-Ae Kim, Hyung Joon Kim, Y. Lee, Jeong-Hoon Lee, N. Park, So Young Kwon, Soo Young Park, Ji Hoon Kim, G. Choi, Eun Sun Jang, Chien-Hung Chen, Yao-Chun Hsu, M.-J. Bair, Pin-Nan Cheng, H. Tung, T. Chang, Ching-Chu Lo, K. Tseng, Sheng-Shun Yang, Cheng-Yuan Peng, Seungbong Han   +26 more
semanticscholar   +1 more source